It is well known that counteraction of the ACVR2B receptor disrupts the signalling mediated by several TGF‐β superfamily members and potently corrects the levels of myostatin, a negative regulator of muscle mass, within skeletal muscle in tumour‐bearing mice.14, 45. The gene discussed is MSTN; the disease is neoplasm.